ÁñÁ«ÊÓƵ

This cohort study examines the incidence of dialysis and acute kidney injury among Medicare beneficiaries after hospitalization for heart failure.

This cohort study evaluates recent reversals in declines in cardiovascular mortality and whether they vary across sociodemographic categories.

This cohort study investigates the prevalence and overlap of cardiac, renal, and metabolic conditions in US adults, using data from the National Health and Nutrition Examination Survey.

This post hoc analysis of a randomized clinical trial evaluates the safety and efficacy of empagliflozin in patients with heart failure and preserved ejection fraction who are taking diuretics.

This cohort study characterizes patterns of sodium-glucose cotransporter-2 inhibitor use among eligible patients hospitalized for heart failure with reduced ejection fraction (HFrEF).

This decision analytical model study quantifies the estimated US population-level impact of reducing heart failure events with sodium-glucose cotransporter-2 inhibitors in left ventricular ejection fraction more than 40%.

This post hoc analysis of a randomized clinical trial of patients with heart failure evaluates the association of empagliflozin with albuminuria levels in study participants.

This narrative review discusses trials evaluating the use of existing chronic heart failure therapies in individuals with recent myocardial infarction and the development of new treatments targeting this population.

This Viewpoint explores how patient-reported response to treatment informs understanding of clinically meaningful outcomes to help establish patient expectations, inform clinical decision-making, and ensure treatment is sound.

This cohort study assesses trends in heart failure–related mortality in Black, Hispanic, and White young adults.

This narrative review explores the use of eGFR slope in clinical trials, its strengths and limitations, and the implications of adopting it as a viable outcome in cardiovascular outcome trials.

This Viewpoint frames the clinical event risk for heart failure in the context of the approach used in the 2018 ACC/AHA cholesterol guidelines.

This cluster randomized trial evaluates the effect of a hospital and postdischarge quality improvement intervention vs usual care on time to heart failure rehospitalization or death, and quality of care, among patients with heart failure and reduced ejection fraction in the US.

This Viewpoint advocates for expanded use of quadruple therapy in patients with heart failure with reduced ejection fraction.

This registry-based cohort study compares the capture of clinically meaningful health status changes between physician-assigned New York Heart Association functional class and patient-reported outcome in Kansas City Cardiomyopathy Questionnaire Overall Summary Score for patients with chronic heart failure with reduced ejection fraction.

This cohort study evaluates the association of heart failure and ischemic heart disease with diabetes complications.

This randomized clinical trial examines intervention to promote self-care in patients with acute heart failure who are discharged from the emergency department.

This cohort study evaluates candidacy for initiation of dapagliflozin based on the US Food and Drug Administration label among contemporary US patients with heart failure with reduced ejection fraction and describes potential barriers to therapeutic optimizations.

This randomized trial compares the effect of the oral soluble guanylate cyclase stimulator vericiguat (15 vs 10 mg/d) vs placebo on change in disease-specific physical function at 24 weeks among patients with HFpEF.

This cross-sectional study describes application of the reverse fragility index in establishing the clinical relevance of published clinical trials with null results.